Sont J K, Han J, van Krieken J M, Evertse C E, Hooijer R, Willems L N, Sterk P J
Department of Pulmonology, Leiden University Hospital, Netherlands.
Thorax. 1996 May;51(5):496-502. doi: 10.1136/thx.51.5.496.
Current guidelines on the management of asthma advocate the use of anti-inflammatory treatment in all but mild disease. They define disease control in terms of clinical criteria such as lung function and symptoms. However, the relationship between the clinical control of the disease and inflammation of the airways is not clear. A cross sectional study was therefore undertaken to investigate the relationship between airways inflammation and measures of clinical control and bronchial hyperresponsiveness in asthmatic patients treated with inhaled steroids.
Twenty six atopic adults (19-45 years) with mild to moderate asthma (baseline forced expiratory volume in one second (FEV1) > or = 50% predicted, concentration of histamine causing a 20% fall in FEV1 (PC20) 0.02-7.6 mg/ml) on regular treatment with inhaled steroids entered the study. Diary card recordings during the two weeks before a methacholine challenge test and bronchoscopic examination were used to determine peak flow variability, symptom scores, and use of beta 2 agonists. Biopsy specimens were taken by fibreoptic bronchoscopy from the carina of the right lower and middle lobes, and from the main carina. Immunohistochemical staining was performed on cryostat sections with monoclonal antibodies against: eosinophil cationic protein (EG1, EG2), mast cell tryptase (AA1), CD45, CD22, CD3, CD4, CD8, CD25, and CD45RO. The number of positively stained cells in the lamina propria was counted twice by using an interactive display system.
There were no differences in cell numbers between the three sites from which biopsy specimens were taken. The PC20 for methacholine was inversely related to the average number of total leucocytes, EG1+, and EG2+ cells, mast cells, CD8+, and CD45RO+ cells in the lamina propria. These relationships were similar for each of the biopsy sites. Symptom scores, beta 2 agonist usage, FEV1, and peak flow variability were not related to any of the cell counts.
Infiltration of inflammatory cells in the lamina propria of the airways seems to persist in asthmatic outpatients despite regular treatment with inhaled steroids. The number of infiltrating leucocytes such as mast cells, (activated) eosinophils, CD8+, and CD45RO+ cells in bronchial biopsy specimens from these patients appears to be reflected by airway hyperresponsiveness to methacholine, but not by symptoms or lung function. These findings may have implications for the adjustment of anti-inflammatory treatment of patients with asthma.
当前哮喘管理指南提倡除轻度疾病外,在所有哮喘患者中使用抗炎治疗。指南依据肺功能和症状等临床标准来定义疾病控制情况。然而,疾病的临床控制与气道炎症之间的关系尚不清楚。因此,开展了一项横断面研究,以调查接受吸入性糖皮质激素治疗的哮喘患者气道炎症与临床控制指标及支气管高反应性之间的关系。
26名年龄在19至45岁之间、患有轻至中度哮喘(基线一秒用力呼气容积(FEV1)≥预计值的50%,组胺浓度使FEV1下降20%(PC20)为0.02 - 7.6mg/ml)且正在接受吸入性糖皮质激素常规治疗的特应性成年患者进入该研究。在进行乙酰甲胆碱激发试验和支气管镜检查前两周,通过日记卡记录来确定呼气峰值流速变异性、症状评分以及β2激动剂的使用情况。通过纤维支气管镜从右下叶和中叶的隆突以及主隆突获取活检标本。对低温恒温切片进行免疫组织化学染色,使用针对嗜酸性粒细胞阳离子蛋白(EG1、EG2)、肥大细胞类胰蛋白酶(AA1)、CD45、CD22、CD3、CD4、CD8、CD25和CD45RO的单克隆抗体。使用交互式显示系统对固有层中阳性染色细胞的数量进行两次计数。
获取活检标本的三个部位的细胞数量没有差异。乙酰甲胆碱的PC20与固有层中总白细胞、EG1 +、EG2 +细胞、肥大细胞、CD8 +和CD45RO +细胞的平均数量呈负相关。每个活检部位的这些关系相似。症状评分、β2激动剂使用情况、FEV1和呼气峰值流速变异性与任何细胞计数均无关联。
尽管接受了吸入性糖皮质激素的常规治疗,但哮喘门诊患者气道固有层中的炎症细胞浸润似乎仍然存在。这些患者支气管活检标本中浸润的白细胞数量,如肥大细胞、(活化的)嗜酸性粒细胞、CD8 +和CD45RO +细胞,似乎可通过气道对乙酰甲胆碱的高反应性反映出来,但不能通过症状或肺功能反映。这些发现可能对哮喘患者抗炎治疗的调整具有启示意义。